Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis
DOI: https://doi.org/10.2147/jaa.s461800
2024-06-07
Journal of Asthma and Allergy
Abstract:Carlo Mümmler, 1 Pontus Mertsch, 1 Michaela Barnikel, 1 Frank Haubner, 2 Ulf Schönermarck, 3 Ulrich Grabmaier, 4 Hendrik Schulze-Koops, 5 Jürgen Behr, 1 Nikolaus Kneidinger, 1, 6 Katrin Milger 1 1 Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center of Lung Research (DZL), Munich, Germany; 2 Department of Otorhinolaryngology, LMU University Hospital, LMU Munich, Munich, Germany; 3 Division of Nephrology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; 4 Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany; 5 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; 6 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria Correspondence: Katrin Milger, Department of Medicine V, LMU University Hospital, Marchioninistr, 15, LMU Munich, Munich, 81377, Germany, Tel +49-89-4400-73071, Email Background: Benralizumab reduces exacerbations and long-term oral glucocorticosteroid (OCS) exposure in patients with severe eosinophilic asthma. In patients with eosinophilic granulomatosis with polyangiitis (EGPA), uncontrolled symptoms and exacerbations of asthma and chronic rhinosinusitis (CRS) are important reasons for continued OCS therapies. We aimed to describe outcomes of patients with severe asthma and EGPA treated with benralizumab in real-life. Methods: We retrospectively analyzed adult patients from the Severe Asthma Unit at LMU Munich diagnosed with severe asthma and EGPA treated with benralizumab, differentiating two groups: Group A, patients with a stable daily OCS dose and diagnosis of EGPA > 6 months ago; and Group B, patients treated with high-dose daily OCS due to recent diagnosis of EGPA < 6 months ago. We compared outcome parameters at baseline and 12 months after initiation of benralizumab, including respiratory exacerbations, daily OCS dose, and lung function. Results: Group A included 17 patients, all receiving OCS therapy and additional immunosuppressants; 15 patients (88%) continued benralizumab for more than 12 months, demonstrating a significant reduction in daily OCS dose and exacerbations while FEV1 increased. Group B included 9 patients, all with high-dose daily OCS and some receiving cyclophosphamide pulse therapy for life-threatening disease. Benralizumab addition during induction was well tolerated. A total of 7/9 (78%) continued benralizumab for more than 12 months and preserved EGPA remission at the 12-month timepoint. Conclusion: In this real-life cohort of patients with severe asthma and EGPA, benralizumab initiation during remission maintenance reduced respiratory exacerbations and daily OCS dose. Benralizumab initiation during remission induction was associated with a high rate of clinical EGPA remission. Keywords: EGPA, asthma, CRS, vasculitis, glucocorticoid, OCS, anti-IL5R, biologics, benralizumab Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg–Strauss syndrome, is a rare systemic vasculitis manifesting with a specific combination of clinical features. It occurs in patients with asthma and eosinophilia after a prodromal phase of varying length, with general symptoms like fever and weight loss marking the onset of systemic inflammatory disease. 1 EGPA mostly affects the respiratory tract with asthma and pulmonary infiltrates as well as upper airway disease, mostly chronic rhinosinusitis with nasal polyps (CRSwNP). Further, it can involve almost every organ, with cutaneous, cardiovascular, neurological, renal, or gastrointestinal manifestations being most frequent. 1,2 Antineutrophil cytoplasmic autoantibodies (ANCA) have been reported in approximately 40% of patients with EGPA in larger, rheumatologic cohorts, usually with specificity against myeloperoxidase (MPO-ANCA) or in rare cases cANCA, 3,4 but in recent trials lower proportions of ANCA-positivity have been observed. 5 EGPA is classified among the ANCA-associated vasculitis syndromes even though (MPO-) ANCA are often negative and vasculitis is not always detectable. 6 Histological characteristics are eosinophilic infiltration and inflammation, necrotizing vasculitis, and extravascular granuloma. 1 Oral glucocorticosteroids (OCS) are the mainstay of treatment in both the remission induction as well as the maintenance phase. 1,7 For remission induction, high-dose OCS and in case of organ- or life-threatening disease add-on cycloph -Abstract Truncated-
immunology,allergy,respiratory system